The Effects of Real-World Evidence on the Treatment of HER2+ mBC - Episode 3

The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC

Jane Meisel, MD, elaborates on the evolution and significance of the antibody-drug conjugate trastuzumab deruxtecan in treating HER2+ metastatic breast cancer, highlighting its effectiveness and considerations for its usage.

EP. 1: Evolution of Advanced HER2+ Breast Cancer Management
EP. 2: Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)
Now Viewing
EP. 3: The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC
EP. 4: Approaches to Sequencing Therapies for HER2+ mBC
EP. 5: Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC
EP. 6: Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC
EP. 7: Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment
EP. 8: Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)
EP. 9: Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan
EP. 10: Novel Therapies Under Investigation for HER2+ mBC
EP. 11: Treatment Sequencing Approaches for Patients With HER2+ mBC
EP. 12: French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC
EP. 13: Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
EP. 14: Treatment Approaches for Patients With HER2+ mBC and Brain Metastases
EP. 15: Novel Treatment Approaches Under Investigation for HER2+ mBC

Related Content:

The Effects of Real-World Evidence on the Treatment of HER2+ mBCBreast CancerOncLive News Network®
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
Dr Feldman on the Significance of the HER2-Low Classification in HER2+ Breast Cancer